Clinical trials · Hartford, CT
Advanced or Metastatic Solid Tumors clinical trials in Hartford
We’re tracking 198 recruiting advanced or metastatic solid tumors studies with a site in or near Hartford — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Hartford
- NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
New Haven, ConnecticutAges 18 years+ - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT06253130RecruitingPhase 1/Phase 2
Study of IMP1734 for Advanced Solid Tumors with HRR Mutations
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
New Haven, ConnecticutAges 18–89 - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
New Haven, ConnecticutAges 12 years+ - NCT06459973RecruitingPhase 1/Phase 2
Study of YL205 for advanced solid tumors
This trial tests a new drug called YL205 for people with certain advanced cancers that have a specific protein (Napi2b) on their cells. It aims to see if the drug is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT06859762RecruitingPhase 1
Study of YL217 for advanced solid tumors
This study tests an experimental drug called YL217 in people with advanced solid tumors that have not responded to other treatments. The drug may work by targeting a protein on cancer cells and delivering a chemotherapy-like agent directly to the tumor, potentially slowing or stopping its growth.
New Haven, ConnecticutAges 18 years+ - NCT06884618RecruitingPhase 1
Study of a new drug for advanced solid tumors with RAS mutations
This trial is testing an experimental drug for people whose cancer has spread and has a specific gene change called RAS. The study aims to see if the drug is safe and helps shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07360314RecruitingPhase 1
A new drug targeting Ly6E for advanced solid tumors
This trial tests a new drug called M7437 that targets a protein (Ly6E) found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests an experimental pill called zongertinib for people with different types of advanced solid tumors that have a specific genetic change called HER2. It's a treatment option when other therapies haven't worked, and it may help shrink or slow the cancer.
New Haven, ConnecticutAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
New Haven, ConnecticutAges 18 years+ - NCT06551220Recruiting
T-DXd for advanced breast cancer with various HER2 levels
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
New Haven, ConnecticutAges 18–80 - NCT07604571RecruitingPhase 1
Testing IEV407 for Advanced Hormone-Sensitive Breast Cancer
This study tests a new drug called IEV407, either alone or combined with existing hormone therapies, in people with advanced breast cancer that is hormone-receptor positive and HER2 negative. The trial aims to find the right dose and see if this combination helps people whose cancer has stopped responding to previous treatments.
New Haven, ConnecticutAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
New Haven, ConnecticutAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
New Haven, ConnecticutAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
New Haven, ConnecticutAges 18 years+ - NCT06270706RecruitingPhase 1
Study of a new drug for advanced solid tumors after immunotherapy
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
New Haven, ConnecticutAges 18 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
New Haven, ConnecticutAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
New Haven, ConnecticutAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
New Haven, ConnecticutAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Hartford, CT
We’ll email you when one opens near Hartford, CT — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Hartford
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Yale University · 16 studies
- Yale-New Haven Hospital (including Smilow Cancer Hospital and Saint Raphael Campus) · 2 studies
- Avenzo Therapeutics Recruiting Site
- Clinical Trial Site
- GSK Investigational Site
- Smilow Cancer Hospital at Yale - New Haven
- Smilow Cancer Hospital Phase 1 Unit
- Yale Cancer Center
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in Connecticut.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Hartford?
- Yes. We're currently tracking 198 recruiting advanced or metastatic solid tumors studies with a site near Hartford, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Hartford?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Hartford to take part?
- Not necessarily. These studies have a site near Hartford, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Hartford regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.